Get Our Top Trade Ideas Delivered Daily - 65% Off Now
get this deal
España
India
Italia
대한민국
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Our Top Trade Ideas Delivered Daily - 65% Off Now
get this deal
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민국
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Jason Kantor
Credit Suisse Sees Solid Q4 Earnings For Kite Pharma
Credit Suisse Sees All Eyes On Eyeguard B Data for XOMA
Credit Suisse Reiterates Neutral, Raises PT On Pharmacyclics As Deal Looks Likely To Happen
Credit Suisse Sees All Eyes On Eyeguard B Data for XOMA
Credit Suisse Reiterates Neutral, Raises PT On Pharmacyclics As Deal Looks Likely To Happen
Credit Suisse Downgrades Pharmacyclics Amid Takeover Rumors
UPDATE: Credit Suisse Raises Price Target On Kite Pharma On AMGN Deal
Credit Suisse Downgrades Pharmacyclics Amid Takeover Rumors
UPDATE: Credit Suisse Raises Price Target On Kite Pharma On AMGN Deal
UPDATE: Credit Suisse Raises PT On Kite Pharma On Strong Outlook For CAR-T
UPDATE: Credit Suisse Downgrades Ariad Pharmaceuticals As Launch Metrics Are Still Weak
Read More...
Jason Kantor Recent News
The Medicines Company Surges Amid Credit Suisse Upgrade
UPDATE: Credit Suisse Downgrades Cubist Pharmaceuticals On Execution Risk To Global Expansion Of Hospital Franchise
XOMA Corp Volatile Amid Differing Analyst Reports
Credit Suisse Expects New Pricing To Boost Sales For Ariad Pharmaceuticals
UPDATE: Credit Suisse Reiterates On Esperion Therapeutics Inc On Multiple Positive Factors
Credit Suisse Sees Continued Operational Progress For Kite Pharma
UPDATE: Credit Suisse Reiterates On BIND Therapeutics After AMGN Declines Option On Accurin Technology
Credit Suisse Raises Q2 Imbruvica Sales Forecast For Pharmacyclics
UPDATE: Credit Suisse Initiates On Alder Biopharmaceuticals, Optimistic On 'Derisked' Assets
UPDATE: Credit Suisse Downgrades The Medicines Company Following Negative Cangrelor Panel
Credit Suisse Reports Ariad's Iclusig is 'Essential Drug'
Credit Suisse Maintains on Cubist Pharmaceuticals
UPDATE: Credit Suisse Raises PT on Ariad Pharmaceuticals, View Remains Cautious
UPDATE: Credit Suisse Reiterates on Ariad Pharmaceuticals as Iclusig Re-Launch is Expected to be Bumpy
UPDATE: Credit Suisse Raises PT on Prothena Following Deal with Roche
UPDATE: Credit Suisse Downgrades Infinity Pharmaceuticals on Limited Clinical News in 2014
UPDATE: Credit Suisse Initiates PTC Therapeutics at Outperform on Bullish Thesis
UPDATE: Credit Suisse Downgrades Spectrum Pharmaceuticals on Limited Growth Opportunities and Increased Risk
UPDATE: Credit Suisse Initiates Portola Pharmaceuticals at Outperform Rating Ahead of PIII APEX Trial